ArticleBMC health services research2025
Barriers and solutions in cross-sector care for metastatic prostate cancer patients in Germany: a qualitative study on radioligand therapy.
Article in BMC health services research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Future opportunities and nuances with the use of PSMA PET in prostate cancer (MD PET 1).Theranostics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn December 2022, Pluvicto® (lutetium(177Lu)-vipivotide tetraxetan) received European Medicine Agency approval based on the Phase III VISION study as the first radioligand therapy (RLT) directed against prostate-specific membrane antigen (PSMA) and using Lutetium-177 (177Lu) for the treatment of metastatic prostate cancer. The objective of this study was to explore current barriers to the provision of 177Lu-PSMA RLT by drawing on the experiences of providers and to outline potential solutions.
methodsEighteen physicians involved in the care of metastatic prostate cancer in the outpatient and inpatient settings from different regions of Germany participated in this semi-structured, qualitative expert interview study. Qualitative content analysis with inductive category formation was used to analyze the data.
resultsFour major thematic categories were identified regarding barriers to care: (a) research-practice gap, (b) challenges to interprofessional collaboration, (c) resource constraints, and (d) unwarranted variation in care. Expert suggestions for resolving these barriers were grouped into the corresponding major thematic categories: (a) knowledge management, (b) integration of care, (c) capacity planning, and (d) facilitation of access.
conclusionsThe delivery of 177Lu-PSMA RLT faces several obstacles, including challenges in collaboration, resource allocation, and reimbursement solutions. Minimizing bureaucratic hurdles in forming healthcare teams is essential to enhance interprofessional coordination. Resources should be evaluated and distributed based on local needs, and expanding reimbursement options for prior diagnostics is critical to ensure early treatment access. Overcoming these barriers and adapting health systems to novel therapies like RLT are essential steps toward improving cancer care and patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.